Shares of Axogen Inc. climbed to a 52-week high of $51.13 on Tuesday, capping a 214.19% gain over the past year as the medical device company reported quarterly results that exceeded analyst expectations.
The peripheral nerve repair specialist posted Q2 2026 revenue of $69.7 million, up 23% year-over-year and surpassing Wall Street’s consensus estimate of $67.1 million. The company reported a net loss of $1.5 million, or $0.03 per share, while adjusted net income totaled $7.3 million, or $0.12 per share.
Analysts at H.C. Wainwright raised their price target to $53, maintaining a buy rating, while Citizens increased its target to $55. Truist Securities initiated coverage with a buy rating and set a $60 target. The stock’s 52-week range stands at $14.79 to $51.13, with a market capitalization of $2.73 billion.
Axogen’s revenue growth of approximately 24% over the trailing twelve months through Q2 2026 underscores its expansion in the peripheral nerve repair market. InvestingPro’s platform analysis indicates the stock is trading near its peak, flagging it as potentially overvalued among the most overvalued companies in its coverage universe.
The company’s performance follows broader gains in select historical AI-driven picks, including Siemens Energy’s 231.5% surge and Sandisk’s 189% advance, though Axogen’s rally outpaced both benchmarks over the same period.
